Gray Nancy Ryan 4
4 · LIGAND PHARMACEUTICALS INC · Filed Nov 12, 2025
Insider Transaction Report
Form 4
Gray Nancy Ryan
Director
Transactions
- Exercise/Conversion
Common Stock
2025-11-07$66.19/sh+3,556$235,372→ 11,650 total - Exercise/Conversion
Non-Qualified Stock Option (right to buy)
2025-11-07−3,556→ 0 totalExercise: $66.19Exp: 2029-06-06→ Common Stock (3,556 underlying) - Sale
Common Stock
2025-11-07$205.45/sh−3,015$619,432→ 8,094 total - Exercise/Conversion
Non-Qualified Stock Option (right to buy)
2025-11-07−3,015→ 0 totalExercise: $73.57Exp: 2027-08-18→ Common Stock (3,015 underlying) - Sale
Common Stock
2025-11-07$205.45/sh−3,556$730,580→ 8,094 total - Exercise/Conversion
Common Stock
2025-11-07$73.57/sh+3,015$221,814→ 11,109 total
Footnotes (2)
- [F1]This Option was previously reported as a Grant of 4,071 shares, which vested in full on June 06, 2020, at an exercise price of $113.5900 per share but was adjusted pursuant to the OmniAb Inc. separation from the issuer.
- [F2]This Option was previously reported as a Grant of 3,452 shares, which vested in full on August 18, 2020, at an exercise price of $126.2600 per share but was adjusted pursuant to the OmniAb Inc. separation from the issuer.